Uncertainties surrounding the efficacy of vaccination to fully prevent transmission against virus variants and concerns of a waning immunity from vaccination and possibly even prior infection require additional safeguards especially among vulnerable individuals. The ability to tailor povidone-iodine use according to exposure risk is a key. At CofixRX we have the right solution in a 10ml bottle ready for you! Povidone-iodine application to the oropharyngeal space could complement existing non-pharmacological interventions to reduce SARS-CoV-2 infection especially in high exposure settings. When applied correctly, povidone-iodine could create a hostile environment for virus replication. Check out the article below.
We searched the electronic databases PubMed, Embase, Cochrane Library, ClinicalTrials.gov and World Health Organization’s International Clinical Trials Registry Platform for articles containing the keywords “povidone-iodine”, “SARS-CoV-2” and “COVID-19” from database inception till 3 June 2021.
The Study
Despite in vitro data supporting the anti-SARS-CoV-2 effects of povidone-iodine, findings from clinical studies revealed differences in treatment response depending on study settings (healthy vs. hospitalized individuals), treatment target (nasal vs. oral vs. pharynx), method of administration (oral rinse vs. gargle vs. throat spray) and choice of samples used to measure study endpoints (nasopharyngeal vs. saliva). One large-scale clinical trial demonstrated reduction in the incidence of SARS-CoV-2 infection among participants who administered povidone-iodine 3 times daily during an active outbreak. Povidone-iodine is also used to disinfect the oro-pharyngeal space prior to dental or otolaryngology procedures. Although existing data suggest minimal impact of povidone-iodine on thyroid function, high-quality safety data are presently lacking.
By coating the oropharynx, povidone-iodine blocks entry of the SARS-CoV-2 virus into host cells and prevents its spread to adjacent tissues.
The Conclusion
Accumulating data suggest antiviral effects of povidone-iodine against the SARS-CoV-2 virus.
Findings from clinical studies reveal differences in treatment response depending on study settings, treatment target, method of administration and choice of samples used to measure study endpoints. One large-scale clinical trial observed reduction in the incidence of SARS-CoV-2 infection among participants who administered povidone-iodine 3 times daily during an active outbreak.
Povidone-iodine application to the oropharyngeal space could complement existing non-pharmacological interventions to reduce SARS-CoV-2 infection especially in high exposure settings.
Read the entire study, with references, diagrams, and technical data at National Library of Medicine website.
